Endo Pharmaceuticals Solutions (IDEV) Inactive 10-Q2006 Q1 Quarterly report

Filed: 9 Feb 06, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: accumulated, Add, anniversary, applied, auction, award, behavior, called, classification, classified, classify, communicated, component, cumulative, curve, database, declared, DELATESTRYL, disclosed, Emerging, enanthate, enroll, equal, European, explained, flexibility, GmbH, gynecology, implied, IND, influence, intellectual, intrinsic, issuer, joint, life, measured, men, middle, modification, modified, noncash, notice, offer, offering, pharmacokinetic, proceed, processed, property, prospective, protocol, reach, reclassification, registration, requisite, retire, retirement, revert, SANCRURA, Savient, service, shelf, specific, submit, summarized, table, Task, therapy, transaction, underlying, unoccupied, unpurchased, vested, volatility, yield

Removed: acquiring, administration, Africa, alternate, amortized, approved, approximated, assessing, automobile, Avenue, blister, blocking, Boston, cessation, commence, commitment, compliance, comply, comprised, consistent, contingency, continued, converting, disposal, disruption, diversified, dosage, dose, Eli, escalation, favorable, feet, female, field, final, Food, forma, formal, Good, Hayden, high, inflammatory, infrastructure, Institute, irritation, Item, iv, lease, Lexington, Lilly, living, local, MA, meet, methodology, monthly, notification, OAB, obligated, occupancy, packaged, pain, partially, Partnership, practice, prescribed, pricing, production, profile, promote, QT, quantity, receipt, recognize, reimburse, rental, reviewed, SAB, safety, sale, Sarafem, scope, square, staffing, standard, stemming, subsidizing, support, termination, transmission, treating, unable, vein, virtue, women, working

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

IDEV similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Indevus Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended December 31, 2005 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael W. Rogers, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.



By:		/s/ Michael W. Rogers
		Chief Financial Officer

February 9, 2006